FOLH1 and hepatocellular carcinoma: In an early clinical study, it was shown that in addition to a good safety profile, patients with advanced HCC treated in that study had prolonged disease stabilization [26] supporting the hypothesis that a PSMA-targeted agent might indeed be particularly effective in HCC.